3,4 For clinicians and patients alike, safety is the first and most pressing concern, especially given the association of peptides with performance enhancement and off-label use
Shepherd noted that women who take medications for weight loss during menopause should pay special attention to their diet and exercise in order to not exacerbate the loss of muscle mass and bone density already common among menopausal women
Originally developed to treat type 2 diabetes, Semaglutide/Ozempic has been found to have the additional benefit of aiding in weight loss for individuals with or without diabetes
Both drugs help manage Type 2 diabetes, but taking two GLP-1 medications at the same time is not recommended
Women may experience rebound weight gain when discontinuing semaglutide or having a missed dose for prolonged time
Persistent constipation, dizziness, vomiting, dehydration, severe abdominal pain, or fainting should always be discussed with a qualified healthcare provider